A5057876995- Cardiac Valve Diseases and Treatments
- Coronary Interventions and Diagnostics
- Infective Endocarditis Diagnosis and Management
- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Cardiovascular Function and Risk Factors
- Cardiac Structural Anomalies and Repair
- Cardiac pacing and defibrillation studies
- Cardiovascular and Diving-Related Complications
- Aortic Disease and Treatment Approaches
- Congenital Heart Disease Studies
- Mechanical Circulatory Support Devices
- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- Hematopoietic Stem Cell Transplantation
- Cerebrovascular and Carotid Artery Diseases
- Blood Pressure and Hypertension Studies
- Cardiac tumors and thrombi
- Peripheral Artery Disease Management
- Antiplatelet Therapy and Cardiovascular Diseases
- CAR-T cell therapy research
- Heart Rate Variability and Autonomic Control
- Coronary Artery Anomalies
- Respiratory Support and Mechanisms
- Heart Failure Treatment and Management
Azienda Ospedaliera San Camillo-Forlanini
2012-2025
Azienda USL di Bologna
2023-2024
University of Bologna
2022-2024
Carlo Forlanini Hospital
2008-2024
IRCCS San Camillo Hospital
2007-2023
Università Cattolica del Sacro Cuore
1991-2023
Azienda Ospedaliera Sant'Andrea
2023
Ospedale generale di zona San Camillo Treviso
2015-2023
Istituto Oncologico Romagnolo
2021
Nini Hospital
2015
Abstract Background and Aims Risk stratification for mitral valve transcatheter edge-to-edge repair (M-TEER) is paramount in the decision-making process to appropriately select patients with severe secondary regurgitation (SMR). This study sought develop validate an artificial intelligence-derived risk score (EuroSMR score) predict 1-year outcomes (survival or survival + clinical improvement) SMR undergoing M-TEER. Methods An was developed from EuroSMR cohort (4172 428 treated M-TEER...
In the last decade, transcatheter aortic valve (TAV) replacement determined a paradigm shift in treatment of patients with severe symptomatic stenosis. Data on long-term TAV performance are still limited. We sought to evaluate clinical and haemodynamic outcomes CoreValve self-expandable up 8-year follow-up (FU).Nine hundred ninety inoperable or high-risk were treated eight Italian Centres from June 2007 December 2011. The median FU was 4.4 years (interquartile range 1.4-6.7 years). Longest...
This study aimed 1) to assess whether patients with an exaggerated blood pressure response the doctor's presence ("white coat" effect) also display a pattern of enhanced reactivity mental stress and physical exercise 2) determine left ventricular structural filling abnormalities in white coat hypertension. We studied 56 (40 men) consecutive (mean [SD] age, 46.4 [9.1] years) whose clinic was repeatedly high. Patients were classified as having hypertension (n = 20) if both their mean daytime...
A risk score was recently derived from the Cardiovascular Outcomes Assessment of MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) Trial. However, external validation this is still lacking.
Abstract Background Procedural success after transcatheter edge‐to‐edge mitral valve repair (TEER) is defined as a reduction of regurgitation (MR) degree to < moderate (2+). However, post‐procedural MR 0/1+ was found be associated with better outcome and lower rate recurrence compared 2+. Aim To evaluate predictors prognostic impact optimal procedural result (MR 0/1+) TEER. Methods The Italian Society Interventional Cardiology (GIse) Registry Transcatheter Treatment Mitral Valve...
BACKGROUND. Predicting Immune-effector Cell Associated Neurotoxicity Syndrome (ICANS) in patients infused with Chimeric Antigen Receptor T cells (CAR-T) is still a conundrum. This complication, thought to be consequent CAR-T cell activation, arises few days after infusion, when circulating are scarce and specific cell-derived biomarkers lacking.
Background: Mitral valve transcatheter edge-to-edge repair (TEER) is a widely adopted therapeutic approach for managing significant mitral regurgitation (MR) in high-risk surgical candidates. While procedural safety and efficacy have been demonstrated, the impact of institutional expertise on outcomes remains unclear. We aimed at evaluating whether monthly volume TEER influences short- long-term clinical results. Methods: This analysis from multicenter, prospective GIOTTO trial study...
Minimally invasive mitral valve repair has a favorable risk-benefit profile in patients with significant de novo regurgitation. Its role prior is uncertain. We aimed to appraise the outcome of undergoing transcatheter edge-to-edge (TEER) or surgical (SMVR).
Objectives To compare the long‐term clinical outcomes of paclitaxel drug‐coated‐balloons (DCB) and everolimus‐eluting‐stents (EES) following treatment de novo small vessel coronary artery disease. Background It is currently unclear whether disease with DCB comparable to second generation drug‐eluting stents, which are current standard care. Methods The present study enrolled 90 patients from arm BELLO (Balloon Elution Late Loss Optimization) trial 2,000 treated EES at San Raffaele Scientific...